Lymphangiosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM008 MIFTS: 40	Lymphangiosarcoma Categories: Cancer diseases, Immune diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Lymphangiosarcoma

MalaCards integrated aliases for Lymphangiosarcoma:

Name: Lymphangiosarcoma ¹² ⁴⁴ ¹⁵ ¹⁷ ⁷⁰

Stewart Treves Syndrome ²⁰ ⁴⁴

Skin Lymphangiosarcoma ¹² ⁷⁰

Angiosarcoma Associated with Chronic Lymphedema ²⁰

Lymphangiosarcoma of Stewart and Treves ¹²

Lymphangiosarcoma Following Mastectomy ²⁰

Postmastectomy Extremity Angiosarcoma ²⁰

Malignant Lymphangioendothelioma ¹²

Stewart-Treves Syndrome ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:2689

MeSH ⁴⁴ C537491 D008204

NCIt ⁵⁰ C3205 C4490

SNOMED-CT ⁶⁷ 403986008 62497000

EFO ¹⁷ EFO_1000339

UMLS ⁷⁰ C0024224 C0346082

Sources

Summaries for Lymphangiosarcoma

GARD : ²⁰ Stewart Treves syndrome is a rare angiosarcoma that develops in people with long-standing lymphedema. Most affected people have a history of breast cancer that was treated with a radical mastectomy. Early signs of the condition vary and may include purplish patches that develop into skin nodules, a mass under the skin, or a poorly healing eschar with recurrent bleeding and oozing. The exact underlying cause of the condition is poorly understood. Although Stewart Treves syndrome is always associated with long-standing lymphedema, other unknown factors also appear to contribute to the development of the condition. Early diagnosis and aggressive surgical treatment may improve the long-term outlook of the condition. Chemotherapy, radiation therapy, and immunotherapy continue to be studied as possible treatment options and may be recommended in some cases.

MalaCards based summary : Lymphangiosarcoma, also known as stewart treves syndrome, is related to hereditary lymphedema i and conventional angiosarcoma. An important gene associated with Lymphangiosarcoma is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways is Angiogenesis (CST). The drugs Mesna and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include lymphatic vessels, endothelial and breast, and related phenotypes are cardiovascular system and digestive/alimentary

Disease Ontology : ¹² A lymphatic system cancer that has material basis in endothelial cells located in lymphatic vessels.

Wikipedia : ⁷³ Lymphangiosarcoma is a rare cancer which occurs in long-standing cases of primary or secondary... more...

Sources

Related Diseases for Lymphangiosarcoma

Diseases related to Lymphangiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)

#	Related Disease	Score	Top Affiliating Genes
1	hereditary lymphedema i	31.1	PROX1 PDPN FLT4
2	conventional angiosarcoma	30.6	PECAM1 CD34
3	histiocytoid hemangioma	30.5	PECAM1 CD34
4	congenital lymphedema	30.3	PDPN FLT4
5	cellulitis	30.3	TNF FLT4
6	keratitis, hereditary	29.9	TNF PECAM1 LYVE1
7	hemangiopericytoma, malignant	29.9	PECAM1 CD34
8	skin angiosarcoma	29.7	TIE1 SNRK FLT4
9	lymphangioma	29.3	PROX1 PECAM1 PDPN LYVE1 FLT4 CD34
10	lymphangitis	29.2	PROX1 PECAM1 PDPN LYVE1 FLT4
11	angiosarcoma	29.2	VWF TIE1 PROX1 PECAM1 PDPN FLT4
12	breast angiosarcoma	28.9	TIE1 SNRK PROX1 PECAM1 FLT4 CD34
13	hemangioma	28.2	VWF TIE1 PROX1 PECAM1 PDPN LYVE1
14	sarcoma	10.4
15	spindle cell sarcoma	10.4
16	radiation proctitis	10.3	TNF PECAM1
17	skin epithelioid hemangioma	10.3	PECAM1 CD34
18	aortic malignant tumor	10.3	PECAM1 CD34
19	prostate angiosarcoma	10.3	PECAM1 CD34
20	central nervous system angiosarcoma	10.3	PECAM1 CD34
21	intravascular angioleiomyoma	10.3	PECAM1 CD34
22	malignant ciliary body melanoma	10.3	PROX1 LYVE1
23	angiokeratoma of fordyce	10.3	PROX1 PECAM1
24	ciliary body cancer	10.3	PROX1 LYVE1
25	central nervous system hemangioma	10.3	PECAM1 CD34
26	heart fibrosarcoma	10.3	PECAM1 CD34
27	ovarian angiosarcoma	10.3	PECAM1 CD34
28	cervical cancer	10.3
29	erysipelas	10.3
30	gallbladder leiomyosarcoma	10.3	PECAM1 CD34
31	thyroid sarcoma	10.3	PECAM1 CD34
32	angiomyoma	10.3	PECAM1 CD34
33	retroperitoneal hemangiopericytoma	10.3	PECAM1 CD34
34	glomangiosarcoma	10.3	PECAM1 CD34
35	hemangioma of spleen	10.3	PECAM1 CD34
36	liposarcoma of bone	10.3	PECAM1 CD34
37	liver leiomyoma	10.3	PECAM1 CD34
38	benign perivascular tumor	10.3	PECAM1 CD34
39	perivascular tumor	10.3	PECAM1 CD34
40	erythema elevatum diutinum	10.3	PECAM1 CD34
41	sarcomatoid squamous cell skin carcinoma	10.3	PECAM1 CD34
42	heart sarcoma	10.3	PECAM1 CD34
43	bacillary angiomatosis	10.3	PECAM1 CD34
44	decubitus ulcer	10.3	TNF PECAM1
45	pulmonary artery leiomyosarcoma	10.2	PECAM1 CD34
46	subungual glomus tumor	10.2	PECAM1 CD34
47	vulvar leiomyoma	10.2	PECAM1 CD34
48	angiolipoma	10.2	PECAM1 CD34
49	intravascular fasciitis	10.2	PECAM1 CD34
50	angiokeratoma circumscriptum	10.2	PECAM1 CD34

Graphical network of the top 20 diseases related to Lymphangiosarcoma:

Sources

Symptoms & Phenotypes for Lymphangiosarcoma

MGI Mouse Phenotypes related to Lymphangiosarcoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.02	FLT4 LYVE1 PDPN PECAM1 PROX1 SNRK
2	digestive/alimentary	MP:0005381	9.87	FLT4 PDPN PECAM1 PROX1 TIE1 TNF
3	hematopoietic system	MP:0005397	9.86	CD34 F8 LYVE1 PDPN PECAM1 PROX1
4	homeostasis/metabolism	MP:0005376	9.85	CD34 F8 FLT4 PDPN PECAM1 PROX1
5	immune system	MP:0005387	9.7	CD34 F8 FLT4 LYVE1 PDPN PECAM1
6	muscle	MP:0005369	9.17	FLT4 PDPN PECAM1 PROX1 SNRK TIE1

Sources

Drugs & Therapeutics for Lymphangiosarcoma

Drugs for Lymphangiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Synonyms:

1-THIOETHANEsulfonate

1-THIOETHANEsulfonIC ACID

1-THIOETHANEsulphonate

1-THIOETHANEsulphonic acid

2 Mercaptoethanesulfonate

2-Mercaptoethane

2-Mercaptoethanesulfonate

2-mercaptoethanesulfonic acid

2-Mercaptoethanesulfonic acid

2-Mercaptoethanesulphonate

2-Mercaptoethanesulphonate, sodium

2-mercaptoethanesulphonic acid

2-Mercaptoethanesulphonic acid

2-mercaptoethylsulfonate

2-Mercaptoethylsulfonate

2-Mercaptoethylsulfonic acid

2-Mercaptoethylsulphonate

2-Mercaptoethylsulphonic acid

2-sulfanylethylsulfonate

2-Sulfanylethylsulfonate

2-Sulfanylethylsulfonic acid

2-Sulphanylethylsulphonate

2-Sulphanylethylsulphonic acid

ASTA D 7093

ASTA medica brand OF mesna

ASTAD 7093

ASTA-D 7093

beta-Mercaptoethanesulfonate

beta-Mercaptoethanesulfonic acid

beta-Mercaptoethanesulphonate

beta-Mercaptoethanesulphonic acid

b-Mercaptoethanesulfonate

b-Mercaptoethanesulfonic acid

b-Mercaptoethanesulphonate

b-Mercaptoethanesulphonic acid

Bristol myers squibb brand OF mesna

Bristol-myers squibb brand OF mesna

Cell pharm brand OF mesna

Coenzima m

Coenzima M

Coenzym m

Coenzym M

Coenzyme m

CoM

HS-CoM

Kendrick brand OF mesna

Mesna

MESNA cell

Mesna kendrick brand

Mesna sanfer brand

MESNA-cell

Mesnex

Mesnum

Mistabron

Mistabronco

Mitexan

Mucofluid

reduced coenzyme M

Reduced coenzyme m

reduced CoM

Reduced com

Sanfer brand OF mesna

Sodium 2-mercaptoethanesulphonate

UCB brand OF mesna

Uromitexan

Ziken

Β-mercaptoethanesulfonate

β-mercaptoethanesulfonic acid

Β-mercaptoethanesulfonic acid

Β-mercaptoethanesulphonate

Β-mercaptoethanesulphonic acid

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-hydroxydaunomycin

14-Hydroxydaunomycin

14-hydroxydaunorubicine

14-Hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

adiblastine (hydrochloride salt)

ADM

ADR

adr iablatina (hydrochloride salt)

Adriablastin

Adriablastine

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin semiquinone

Adriamycin Semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (hydrochloride salt)

Adriblastina (TN)

Adriblastine

adriblatina (hydrochloride salt)

Adrimedac

Aerosolized Doxorubicin

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

BPBio1_000502

BRD-K92093830-003-04-3

Bristol-myers squibb brand OF doxorubicin hydrochloride

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

Caelyx

CCRIS 739

Cell pharm brand OF doxorubicin hydrochloride

CHEBI:28748

CHEMBL179

CID31703

Columbia brand OF doxorubicin hydrochloride

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

Doxil

Doxo

Doxo cell

Doxo-cell

Doxolem

doxorubicin

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin Hydrochloride

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

DOX-SL

EINECS 245-495-6

Elan brand OF doxorubicin hydrochloride

Farmablastina (hydrochloride salt)

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

FI 106

Hexal brand OF doxorubicin hydrochloride

HMS2089H06

HSDB 3070

Hydrochloride, doxorubicin

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

LMPK13050001

LS-1029

LS-165655

Medac brand OF doxorubicin hydrochloride

MLS000759533

Myocet

NChemBio.2007.10-comp13

nchembio809-comp5

NCI-C01514

NDC 38242-874

Neocorp brand OF doxorubicin hydrochloride

NIOSH/JT9100000

NSC 123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

Tedec meiji brand OF doxorubicin hydrochloride

ThermoDox

TLC D-99

Triferric doxorubicin

UNII-80168379AG

Urokit doxo cell

Urokit doxo-cell

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Synonyms:

(+-)-Ifosfamid

(+-)-Ifosphamide

(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

(D,L)-Ifosfamide

(R,S)-Ifosphamide

(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3,} 2-oxazaphosphorine oxide

36341-88-5

3778-73-2

84711-20-6

A 4942

AB00513932

AC1L1GHW

AC-2113

Ambap3778-73-2

Asta Z 4942

ASTA Z 4942

BPBio1_000865

BRN 0611835

BSPBio_000785

C07047

CAS-3778-73-2

CCRIS 352

CHEBI:5864

CHEMBL1024

CID3690

Cyfos

D00343

D007069

DB01181

EINECS 223-237-3

HMS1570H07

HMS2090M12

HMS2093N07

Holoxan

Holoxan 1000

HSDB 7023

I06-0494

Ifex

IFEX (TN)

Ifosfamid

Ifosfamida

Ifosfamida [INN-Spanish]

ifosfamide

Ifosfamide

Ifosfamide (JAN/USP/INN)

Ifosfamide [USAN:INN:BAN:JAN]

Ifosfamide sterile

Ifosfamide Sterile

Ifosfamidum

Ifosfamidum [INN-Latin]

Ifosphamide

Ifsofamide

Iphosphamid

Iphosphamid(e)

Iphosphamide

I-phosphamide

I-Phosphamide

Iso endoxan

Iso Endoxan

Isoendoxan

Iso-endoxan

Iso-Endoxan

Isofosfamide

Isophosphamide

isosfamide

Isosfamide

LS-102

LS-99799

Mitoxana

Mitoxana, Ifex, Ifosfamide

MJF 9325

MJF-9325

MLS002154021

MolPort-003-666-704

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide

N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide

Naxamide

NCGC00016639-01

NCGC00179435-01

NCI60_000233

NCI-C01638

NPFAPI-04

NSC 109,724

NSC 109724

NSC109,724

NSC-109,724

NSC109724

NSC-109724

Prestwick0_000833

Prestwick1_000833

Prestwick2_000833

Prestwick3_000833

S1302_Selleck

SMR001233348

SPBio_002706

STL058690

UNII-UM20QQM95Y

WLN: T6NPOTJ AM2G BO B2G

Z 4942

Z4942

Z-4942

Liposomal doxorubicin

Phase 2

31703

Isophosphamide mustard

Phase 2

100427

Synonyms:

Ifosfamide mustard

Ifosforamide mustard

IPAM

Iphosphoramide mustard

Isophosphamide mustard

Isophosphoramide mustard

N,N'-di-(2-chloroethyl)phosphorodiamidic acid

NN'-Bis-(2-chloroethyl)phosphate

NN'-Bis-(2-chloroethyl)phosphoric acid

Palifosfamide

Palifosfamide-tris

Zio-201isophosphamide mustard

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	Active, not recruiting	NCT03651375	Phase 2	Sequential chemotherapy - 3 courses of AI

Search NIH Clinical Center for Lymphangiosarcoma

Cochrane evidence based reviews: lymphangiosarcoma

Sources

Genetic Tests for Lymphangiosarcoma

Sources

Anatomical Context for Lymphangiosarcoma

The Foundational Model of Anatomy Ontology organs/tissues related to Lymphangiosarcoma:

¹⁹

Lymphatic Vessels

MalaCards organs/tissues related to Lymphangiosarcoma:

⁴⁰

Endothelial, Breast, Skin, Bone, Lymph Node, Bone Marrow, Spinal Cord

Sources

Publications for Lymphangiosarcoma

Articles related to Lymphangiosarcoma:

(show top 50) (show all 468)

#	Title	Authors	PMID	Year
1	Stewart-Treves Syndrome as a Rare and Fatal Complication of Post-Traumatic Lymphedema on the Lower Extremity. ⁶¹	Leite LL...Rossato V	33747618	2021
2	Shoulder arthroplasty in patients with upper extremity lymphedema may result in transient or permanent lymphedema worsening. ⁶¹	Lee J...Sanchez-Sotelo J	33343716	2020
3	Stewart-Treves syndrome: Case report and literature review. ⁶¹	Vojtisek R...Finek J	33088229	2020
4	A case of Stewart-Treves syndrome occurring in the abdominal wall successfully treated with eribulin: A case report. ⁶¹	Imura Y...Takenaka S	32874579	2020
5	Stewart-Treves syndrome: a rapidly fatal complication of breast cancer treatment. ⁶¹	Hsu A...Dizon DS	33002445	2020
6	Scalp lymphangiosarcoma: A distinct skin manifestation of edematous erythema on face and scalp without subcutaneous hemorrhage or preceding condition of lymphedema. ⁶¹	Suzuki H...Aiba S	32677036	2020
7	Primary Lymphangiosarcoma of the Urinary Bladder in a Dog. ⁶¹	Michishita M...Azakami D	32958144	2020
8	Adipose-derived stem cell therapy shows promising results for secondary lymphedema. ⁶¹	Hu LR...Pan J	32843917	2020
9	Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation. ⁶¹	Yang F...Guan JL	32336756	2020
10	Pathologic and flow cytometric features of a case of canine ventral cervical lymphangiosarcoma. ⁶¹	Azevedo CN...Russell KE	32306890	2020
11	Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome. ⁶¹	Hayashi M...Shimizu T	32250262	2020
12	IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation. ⁶¹	Yoshida S...Aiba S	32508617	2020
13	Secondary angiosarcoma: A fatal complication of chronic lymphedema. ⁶¹	Farzaliyev F...Podleska LE	31236970	2020
14	A case of Stewart-Treves Syndrome of the lower limbs: The usefulness of dermoscopy. ⁶¹	Marasca C...Megna M	31407462	2019
15	Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib. ⁶¹	Yamada M...Manabe M	30802322	2019
16	Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC). ⁶¹	Taffurelli M...Galimberti V	30877870	2019
17	Unsuspected Stewart-Treves syndrome clinically mimicked by apparent bullous erysipelas and a systematic review of dermatological presentations of the classical Stewart-Treves syndrome. ⁶¹	da Costa Vieira RA...da Silva SRM	32721135	2019
18	Primary Lymphedema of the Upper Extremities: Clinical and Lymphoscintigraphic Features in 23 Patients. ⁶¹	Goss JA...Greene AK	30280960	2019
19	Clinicopathologic features of Stewart-Treves syndrome. ⁶¹	Wang LL...Jiang ZC	31933875	2019
20	Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. ⁶¹	Requena C...Llombart B	30262126	2018
21	Cutaneous angiosarcoma of the lower leg. ⁶¹	Scholtz J...Simman R	30489569	2018
22	Cutaneous Angiosarcoma Postmastectomy (Stewart-Treves Syndrome). ⁶¹	Degrieck B...Crevits I	30320298	2018
23	Guillain-Barré syndrome in a cancer patient treated with bevacizumab. ⁶¹	Taguchi D...Shibata H	31149522	2018
24	Metastatic Angiosarcoma of Lower Extremity. ⁶¹	Tambe SA...Nayak CS	29854638	2018
25	[Angiosarcoma in primary lymphoedema: A rare complication]. ⁶¹	Farhat MM...Modiano P	29530502	2018
26	Pretibial Located Stewart-Treves Syndrome: Uncommon Presentation in a Bulgarian Patient! ⁶¹	Tchernev G...Tronnier M	29731936	2018
27	Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor. ⁶¹	Kim JH...Kim JH	29606721	2018
28	Angiosarcoma complicating lower leg elephantiasis in a male patient: An unusual clinical complication, case report and literature review. ⁶¹	Shavit E...Sibbald RG	30397474	2018
29	A Supernumerary Nipple-Like Clinical Presentation of Lymphangioma Circumscriptum. ⁶¹	Taylor D...Silapunt S	29796322	2018
30	Stewart-Treves syndrome: Magnetic resonance imaging data compared with pathological results from a single center. ⁶¹	Li B...Wang Z	29391898	2018
31	Lymphangiosarcoma of the hip arising in a congenital non-irradiated lymphangioma. ⁶¹	Miyagawa T...Sato S	29068520	2017
32	Stewart-Treves Syndrome on the Lower Extremity Associated to Idiopathic Chronic Lymphedema Visualized on FDG PET/CT. ⁶¹	Brittain JM...Andersen KF	29035997	2017
33	Morphofunctional basis of the different types of angiogenesis and formation of postnatal angiogenesis-related secondary structures. ⁶¹	Diaz-Flores L...Madrid JF	28762232	2017
34	Stewart-Treves syndrome in a spinal cord injury patient with MYC amplification. ⁶¹	Fischer AS...Cohen DN	29264380	2017
35	Pathology in Practice. Ventral abdominal lymphangiosarcoma. ⁶¹	Lin D...Jennings SH	28263114	2017
36	Cutaneous angiosarcoma: report of three different and typical cases admitted in a unique dermatology clinic. ⁶¹	Cabral ANF...Diniz LM	28538886	2017
37	Stewart-Treves Syndrome Involving Chronic Lymphedema after Mastectomy of Breast Cancer. ⁶¹	Mesli SN...Abi-Ayad C	28280645	2017
38	Lymphangiosarcoma of the jejunum in a 44-year-old man: report of a case and review of literature. ⁶¹	Hou J...Shi C	31966736	2017
39	MYC immunohistochemistry in angiosarcoma and atypical vascular lesions: practical considerations based on a single institutional experience. ⁶¹	Udager AM...Patel RM	27780597	2016
40	A case of Stewart-Treves syndrome with the longest lag: 44 years after radical mastectomy for breast cancer. ⁶¹	Inamura Y...Shimizu H	29896826	2016
41	An unusual presentation of Stewart-Treves syndrome on the lower extremity. ⁶¹	Whitney K...LaFond AA	27766300	2016
42	The use of novel lymphatic endothelial cell-specific immunohistochemical markers to differentiate cutaneous angiosarcomas in dogs. ⁶¹	Halsey CH...Ehrhart EJ	24593773	2016
43	Pancreatic metastasis of angiosarcoma (Stewart-Treves syndrome) diagnosed using endoscopic ultrasound-guided fine needle aspiration: A case report. ⁶¹	Sasajima J...Okumura T	27537557	2016
44	Angiosarcoma after excisional surgery for chronic lymphedema. ⁶¹	Joh JH...Lee HY	27318054	2016
45	Modeling lymphangiosarcoma in mice. ⁶¹	Sun S...Guan JL	27105012	2016
46	Lymphangiosarcoma in 12 dogs: a case series (1998-2013). ⁶¹	Curran KM...Worley DR	24612140	2016
47	Lymphangiosarcoma: Is Stewart-Treves Syndrome a Preventable Condition? ⁶¹	Felmerer G...Aung T	26584023	2016
48	Angiosarcoma on Lymphedema (Stewart-Treves Syndrome): A 12-Year Follow-up after Isolated Limb Perfusion, Limb Infusion, and Electrochemotherapy. ⁶¹	Campana LG...Aliberti C	26916941	2016
49	Stewart Treves Syndrome in a Woman with Mastectomy. ⁶¹	Alan S...Erol H	27042566	2016
50	Stewart-Treves Syndrome: A Case Report and Review of the Literature. ⁶¹	Berebichez-Fridman R...Kett DH	27099606	2016

Sources

Genes for Lymphangiosarcoma

Genes related to Lymphangiosarcoma (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TNF	Tumor Necrosis Factor	Protein Coding	10.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	7.1	DISEASES inferred ¹⁵
3	PROX1	Prospero Homeobox 1	Protein Coding	7.03	DISEASES inferred ¹⁵
4	LYVE1	Lymphatic Vessel Endothelial Hyaluronan Receptor 1	Protein Coding	6.74	DISEASES inferred ¹⁵
5	CD34	CD34 Molecule	Protein Coding	6.5	DISEASES inferred ¹⁵
6	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	6.32	DISEASES inferred ¹⁵
7	PDPN	Podoplanin	Protein Coding	5.95	DISEASES inferred ¹⁵
8	VWF	Von Willebrand Factor	Protein Coding	5.6	DISEASES inferred ¹⁵
9	TIE1	Tyrosine Kinase With Immunoglobulin Like And EGF Like Domains 1	Protein Coding	5.46	DISEASES inferred ¹⁵
10	SNRK	SNF Related Kinase	Protein Coding	5.46	DISEASES inferred ¹⁵
11	F8	Coagulation Factor VIII	Protein Coding	5.42	DISEASES inferred ¹⁵

Sources

Variations for Lymphangiosarcoma

Sources

Expression for Lymphangiosarcoma

Search GEO for disease gene expression data for Lymphangiosarcoma.

Sources

Pathways for Lymphangiosarcoma

Pathways related to Lymphangiosarcoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Angiogenesis (CST) ⁴	10.97	VWF PROX1 PECAM1 PDPN FLT4

Sources

GO Terms for Lymphangiosarcoma

Cellular components related to Lymphangiosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.17	TNF TIE1 PECAM1 PDPN LYVE1 FLT4

Biological processes related to Lymphangiosarcoma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	multicellular organism development	GO:0007275	9.88	TNF TIE1 PROX1 PDPN FLT4
2	positive regulation of protein phosphorylation	GO:0001934	9.69	TNF PECAM1 FLT4
3	leukocyte migration	GO:0050900	9.67	TNF PECAM1 CD34
4	cell-cell adhesion	GO:0098609	9.63	PECAM1 PDPN CD34
5	platelet degranulation	GO:0002576	9.58	VWF PECAM1 F8
6	platelet activation	GO:0030168	9.5	VWF PDPN F8
7	blood coagulation, intrinsic pathway	GO:0007597	9.43	VWF F8
8	lymph vessel development	GO:0001945	9.37	PROX1 FLT4
9	lymphatic endothelial cell differentiation	GO:0060836	9.26	TIE1 PROX1
10	glomerular endothelium development	GO:0072011	9.16	PECAM1 CD34
11	lymphatic endothelial cell fate commitment	GO:0060838	8.96	PROX1 PDPN
12	lymphangiogenesis	GO:0001946	8.8	PROX1 PDPN FLT4

Sources

Sources for Lymphangiosarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia